ArticleFrontiers in health services2025
Impact of birth defect prevention and control programs on mortality among children with birth defects from 2012 to 2023 in Shenzhen, China.
Article in Frontiers in health services, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Birth defects are an important cause of fetal and neonatal mortality and represent a major global public health concern. Shenzhen has implemented several prevention and control programs in recent years. However, the effectiveness in reducing mortality among affected children has not been systematically evaluated. Objective: To assess the impact of birth defect prevention and control programs on mortality among children with birth defects in Shenzhen from 2012 to 2023, and to provide evidence for program evaluation and maternal-child health policy development. Methods: All registered cases of children with birth defects in Shenzhen between 2012 and 2023 were included. The study period was divided into three phases according to program implementation: Phase I (2012-2017), Phase II (2018-2021), and Phase III (2022-2023). Mortality outcomes included early fetal death, late fetal death, and early neonatal death. Trends were analyzed using the Cochran-Armitage test with Bonferroni-adjusted pairwise comparisons. Multivariable logistic regression adjusted for confounders and subgroup analyses were conducted by maternal household registration status (local vs. non-local). Results: From Phase I to Phase III, early fetal mortality increased (26.1% vs. 29.7% vs. 33.4%), whereas late fetal mortality (5.7% vs. 4.1% vs. 3.6%) and early neonatal mortality (1.0% vs. 0.5% vs. 0.3%) declined significantly( Conclusion: Birth defect prevention and control programs in Shenzhen were associated with reduced late fetal and early neonatal mortality, especially in non-local populations, Providing evidence to guide maternal-child health policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.